Cargando…
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study
INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and safety o...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060482/ https://www.ncbi.nlm.nih.gov/pubmed/36892752 http://dx.doi.org/10.1007/s13555-023-00906-2 |
_version_ | 1785017100589334528 |
---|---|
author | Fernandez-Crehuet, Pablo Haselgruber, Sofía Padial-Gomez, Alicia Vasquez-Chinchay, Fiorella Fernandez-Ballesteros, Maria Dolores López-Riquelme, Irene Jimenez-Gallo, David Segura-Palacios, Juan Manuel Contreras-Steyls, Marisol Osorio-Gómez, Giovana Fernanda Hernández-Rodríguez, Juan Carlos Sanchez-Diaz, Manuel Cuenca-Barrales, Carlos Arias-Santiago, Salvador Molina-Leyva, Alejandro |
author_facet | Fernandez-Crehuet, Pablo Haselgruber, Sofía Padial-Gomez, Alicia Vasquez-Chinchay, Fiorella Fernandez-Ballesteros, Maria Dolores López-Riquelme, Irene Jimenez-Gallo, David Segura-Palacios, Juan Manuel Contreras-Steyls, Marisol Osorio-Gómez, Giovana Fernanda Hernández-Rodríguez, Juan Carlos Sanchez-Diaz, Manuel Cuenca-Barrales, Carlos Arias-Santiago, Salvador Molina-Leyva, Alejandro |
author_sort | Fernandez-Crehuet, Pablo |
collection | PubMed |
description | INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and safety of secukinumab in patients with moderate to severe HS after 16 weeks of treatment, and to explore potential predictors of clinical response to the drug. METHODS: Multicenter observational retrospective study. Patients treated with secukinumab 300 mg every 2 or 4 weeks who had completed at least 16 weeks of follow-up from nine hospitals based in southern Spain (Andalusia) were included in this study. Treatment effectiveness was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR). Information about adverse events was collected, the therapeutic burden of the patients was calculated as the summation of systemic medical treatments and surgical interventions (excluding incision and drainage) experienced until the start of secukinumab treatment. RESULTS: Forty-seven patients with severe HS were included for analysis. At week 16, 48.9% (23/47) of patients achieved HiSCR. Adverse events were present in 6.4% (3/47) of the patients. The multivariate analysis showed that female sex and, to a lesser extent, lower body mass index (BMI) and a lower therapeutic burden were potentially associated with a higher probability of HiSCR achievement. CONCLUSIONS: Favorable short-term effectiveness and safety of secukinumab in the treatment of severe HS patients were observed. Female sex, lower BMI and a lower therapeutic burden may be associated with a higher probability of achieving HiSCR. |
format | Online Article Text |
id | pubmed-10060482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-100604822023-03-31 Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study Fernandez-Crehuet, Pablo Haselgruber, Sofía Padial-Gomez, Alicia Vasquez-Chinchay, Fiorella Fernandez-Ballesteros, Maria Dolores López-Riquelme, Irene Jimenez-Gallo, David Segura-Palacios, Juan Manuel Contreras-Steyls, Marisol Osorio-Gómez, Giovana Fernanda Hernández-Rodríguez, Juan Carlos Sanchez-Diaz, Manuel Cuenca-Barrales, Carlos Arias-Santiago, Salvador Molina-Leyva, Alejandro Dermatol Ther (Heidelb) Original Research INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and safety of secukinumab in patients with moderate to severe HS after 16 weeks of treatment, and to explore potential predictors of clinical response to the drug. METHODS: Multicenter observational retrospective study. Patients treated with secukinumab 300 mg every 2 or 4 weeks who had completed at least 16 weeks of follow-up from nine hospitals based in southern Spain (Andalusia) were included in this study. Treatment effectiveness was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR). Information about adverse events was collected, the therapeutic burden of the patients was calculated as the summation of systemic medical treatments and surgical interventions (excluding incision and drainage) experienced until the start of secukinumab treatment. RESULTS: Forty-seven patients with severe HS were included for analysis. At week 16, 48.9% (23/47) of patients achieved HiSCR. Adverse events were present in 6.4% (3/47) of the patients. The multivariate analysis showed that female sex and, to a lesser extent, lower body mass index (BMI) and a lower therapeutic burden were potentially associated with a higher probability of HiSCR achievement. CONCLUSIONS: Favorable short-term effectiveness and safety of secukinumab in the treatment of severe HS patients were observed. Female sex, lower BMI and a lower therapeutic burden may be associated with a higher probability of achieving HiSCR. Springer Healthcare 2023-03-09 /pmc/articles/PMC10060482/ /pubmed/36892752 http://dx.doi.org/10.1007/s13555-023-00906-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Fernandez-Crehuet, Pablo Haselgruber, Sofía Padial-Gomez, Alicia Vasquez-Chinchay, Fiorella Fernandez-Ballesteros, Maria Dolores López-Riquelme, Irene Jimenez-Gallo, David Segura-Palacios, Juan Manuel Contreras-Steyls, Marisol Osorio-Gómez, Giovana Fernanda Hernández-Rodríguez, Juan Carlos Sanchez-Diaz, Manuel Cuenca-Barrales, Carlos Arias-Santiago, Salvador Molina-Leyva, Alejandro Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study |
title | Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study |
title_full | Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study |
title_fullStr | Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study |
title_full_unstemmed | Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study |
title_short | Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study |
title_sort | short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060482/ https://www.ncbi.nlm.nih.gov/pubmed/36892752 http://dx.doi.org/10.1007/s13555-023-00906-2 |
work_keys_str_mv | AT fernandezcrehuetpablo shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT haselgrubersofia shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT padialgomezalicia shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT vasquezchinchayfiorella shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT fernandezballesterosmariadolores shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT lopezriquelmeirene shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT jimenezgallodavid shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT segurapalaciosjuanmanuel shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT contrerassteylsmarisol shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT osoriogomezgiovanafernanda shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT hernandezrodriguezjuancarlos shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT sanchezdiazmanuel shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT cuencabarralescarlos shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT ariassantiagosalvador shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy AT molinaleyvaalejandro shorttermeffectivenesssafetyandpotentialpredictorsofresponseofsecukinumabinpatientswithseverehidradenitissuppurativarefractorytobiologictherapyamulticenterobservationalretrospectivestudy |